Natera's Signatera Validated as Superior to PET/CT in Lymphoma MRD Assessment — Natera, Inc.

Event summary

Natera's Signatera demonstrated superior prognostic ability over PET/CT in lymphoma patients, with end-of-treatment positivity strongly predicting inferior event-free survival (adj HR: 45.33; p<0.0001).
The study evaluated 144 patients across 14 lymphoma subtypes, analyzing 1,105 plasma samples, and found Signatera had a 100% positive predictive value vs. PET/CT's 62% at end-of-treatment.
Signatera clearance during first-line therapy was associated with significantly improved event-free survival (adj HR: 8.57; p=0.0005).
For relapsed/refractory patients post CAR-T therapy, Signatera-positive patients had a median durable treatment interval of 1.97 months vs. 16.1 months for Signatera-negative patients.

The big picture

The study validates Natera's Signatera as a more reliable tool for molecular residual disease (MRD) assessment in lymphoma, addressing limitations of current imaging standards like PET/CT. This positions Signatera as a potential standard-of-care adjunct, aligning with broader industry shifts toward precision medicine and personalized cancer treatment. The findings could accelerate adoption of ctDNA-based MRD testing, particularly as guidelines like those from NCCN increasingly incorporate such molecular assessments.

What we're watching

Adoption Dynamics: How quickly Natera can integrate Signatera into routine clinical practice for lymphoma management, given the study's strong validation.
Reimbursement Hurdles: Whether payers will cover Signatera testing given its superior prognostic and predictive value over existing imaging standards.
Competitive Positioning: The pace at which Natera can expand Signatera's use across other cancer types beyond lymphoma, leveraging this validation.